Scientists Create CRISPR Tool That Targets Only Cancer Cells
Wageningen, Wednesday, 15 April 2026.
Wageningen University researchers have developed ThermoCas9, a CRISPR variant that exploits methylation differences to selectively cut tumor DNA while leaving healthy cells untouched. This breakthrough addresses cancer’s ability to hide from detection by targeting subtle chemical markers.
Breakthrough in Medical Biotechnology
This development represents a significant advancement in medical biotechnology, specifically in the field of precision cancer therapy. The research, published today in Nature, demonstrates how scientists have successfully engineered a CRISPR variant to address one of cancer treatment’s most persistent challenges: distinguishing malignant cells from healthy tissue [1]. Cancer cells are masters at concealing themselves, but they occasionally reveal their presence through subtle chemical differences compared to healthy cells, which this new technology exploits [1].
How ThermoCas9 Technology Works
The innovation centers on ThermoCas9’s unique ability to detect genes that are methylated in healthy cells but not in tumor cells [1]. ThermoCas9 binds to DNA through a short recognition code called a PAM (Protospacer Adjacent Motif) that contains a methylation site [1]. When a methyl group is present on the DNA, it disrupts the molecular fit of ThermoCas9, preventing the tool from binding and cutting [1]. This mechanism allows the system to cut DNA specifically in tumor cells while leaving healthy cells completely unharmed [1]. “This CRISPR variant is the first to respond to methylation differences. This means we have a system that we can specifically direct toward tumor cells,” explains John van der Oost, the lead researcher at Wageningen University [1].
International Collaboration and Research Timeline
The breakthrough emerged from a collaboration between Wageningen University researchers and American colleagues, with Dr. Hong Li from the Van Andel Institute in Michigan, United States, serving as a key partner [1][2]. ThermoCas9 was originally discovered in bacteria several years ago by the Wageningen University team [1]. The research has already secured significant funding support, with van der Oost and Christian Südfeld receiving an ERC Proof of Concept grant in late January 2026 for follow-up research [1]. Dr. Li emphasizes the potential impact: “ThermoCas9 uses methylation as a kind of address to accurately target cancer cells, while healthy cells remain untouched. These findings could be a game changer” [1].
Clinical Applications and Future Prospects
The technology’s benefits extend beyond traditional cancer treatment applications. ThermoCas9 or similar CRISPR tools could potentially address other diseases characterized by abnormal methylation patterns, including childhood cancers such as neuroblastoma and various autoimmune diseases [1]. However, researchers maintain realistic expectations about implementation timelines. Van der Oost cautions that “it will probably take at least ten years before such therapy becomes available to patients” [1]. This extended timeline reflects the rigorous testing and regulatory approval processes required for revolutionary medical treatments, ensuring both safety and efficacy before reaching clinical practice.